Eva Temkin to Speak at Fierce Biotech Summit

Washington, D.C. FDA and Life Sciences partner Eva Temkin will present at the Fierce Biotech Summit on the Case Study “Industry Response to Mifepristone Ruling and What It Means to Take a Stand in Today's Political Climate” on Oct. 17.  This presentation will delve into the multifaceted impact of U.S. District Judge Matthew Kacsmayrk’s unprecedented ruling to suspend FDA approval of mifepristone. It highlights the remarkable industry response that ensued, showcasing various initiatives and strategies employed to address the ruling and protect patient access to critical healthcare options. Moreover, it explores the significance of the Biotech Social Pact, stakeholder capitalism, and why the industry must actively engage in advocacy efforts against policies that jeopardize human health. The mifepristone efforts serve as a compelling blueprint for future activism within the biotech sector.